ArticlePharmaceuticals (Basel, Switzerland)2024
Quercetin and Kaempferol as Multi-Targeting Antidiabetic Agents against Mouse Model of Chemically Induced Type 2 Diabetes.
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Efficacy of Xiaokeqing granules and lifestyle intervention in treating prediabetes mellitus considering metabolomic biomarkers: A randomised controlled trial.World journal of diabetes · 2025Trial
- Antioxidants as a Link Between Diabetes and Potential Plant-Based Therapies.Antioxidants (Basel, Switzerland) · 2026Review
- Regulatory Roles of Kaempferol on the PI3K/AKT/mTOR Signaling Pathway and Associated MicroRNAs in Different Cancer Types.International journal of molecular sciences · 2026Review
- Additive Effects of Quercetin-RichPharmaceuticals (Basel, Switzerland) · 2026Article
- Molecular Docking of Natural Compounds as DPP-4 Inhibitors in Type 2 Diabetes: A Comprehensive Review.Pharmaceutics · 2026Review
- Chlorogenic acid and gallic acid synergistically reduce hyperglycemia and hyperlipidemia in diabetic BALB/c mice.Scientific reports · 2026Article
- Quercetin and Its Nano-Based Formulations Against Skin Cancer: A Narrative Review.Health science reports · 2026Article
- Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus.Pharmaceutics · 2026Review
- Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development.Frontiers in endocrinology · 2026Review
- Antioxidant, Antibacterial, and Antidiabetic Activities ofTheScientificWorldJournal · 2026Article
- An Insight on Flavonoids and Flavonoidsincorporated Nano-formulations in the Management of Diabetes Mellitus.Current diabetes reviews · 2026Review
- A protocol for the impact of Tongmai Jiangtang capsules on the risk of cardiovascular and cerebrovascular events in metabolic syndrome.Frontiers in cardiovascular medicine · 2026Article
- A multimodal caffeic acid-derived alkyl-amide antidiabetic agent: targeting α-glucosidase, α-amylase, oxidative stress, and protein glycation.RSC advances · 2025Article
- Exploring the Mechanisms ofInternational journal of molecular sciences · 2025Article
- Bioprospection of indigenous herbal formulations for diabetes care: in vitro, network pharmacology, and molecular dynamics studies.BMC complementary medicine and therapies · 2025Article
- Flavonoids, Chalcones, and Their Fluorinated Derivatives-Recent Advances in Synthesis and Potential Medical Applications.Molecules (Basel, Switzerland) · 2025Review
- Analysis of Antioxidant Activity and Volatile Components in Rapeseed Flower-Enriched Persimmon Wine.Foods (Basel, Switzerland) · 2025Article
- Multitargeted Effects ofInternational journal of molecular sciences · 2025Article
- Antioxidant, Alpha-Amylase Inhibitory and Hypoglycemic Activity ofFood science & nutrition · 2025Article
- Investigation Into the Impact of Solvents on the Phytochemical Composition, Antioxidant Capacities, and Antihyperglycemic Activities ofBioMed research international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diabetes, a multifactorial metabolic disorder, demands the discovery of multi-targeting drugs with minimal side effects. This study investigated the multi-targeting antidiabetic potential of quercetin and kaempferol. The druggability and binding affinities of both compounds towards multiple antidiabetic targets were explored using pharmacokinetic and docking software (AutoDock Vina 1.1.2). Our findings showed that quercetin and kaempferol obey Lipinski's rule of five and exhibit desirable ADMET (absorption, distribution, metabolism excretion, and toxicity) profiles. Both compounds showed higher binding affinities towards C-reactive protein (CRP), interleukin-1 (IL-1), dipeptidyl peptidase-4 (DPP-IV), peroxisome proliferator-activated receptor gamma (PPARG), protein tyrosine phosphatase (PTP), and sodium-glucose co-transporter-1 (SGLT-1) compared to metformin (the positive control). Both quercetin and kaempferol inhibited α-amylase activity (in vitro) up to 20.30 ± 0.49 and 37.43 ± 0.42%, respectively. Their oral supplementation significantly reduced blood glucose levels (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.